In the present study, we demonstrated the ability of ADAM9 shRNA impaired androgen-independent prostate cancer PC3 tumor formation and cancer-induced osteolysis in a skeletal metastasis xenograft model. Here, ADAM9 is linked to prostate carcinoma.